The scaffolding protein WWC (WW and C2-domain containing) family is known to regulate cell proliferation and organ size via the Hippo signalling pathway. However, the expression level of WWC3 in human tumours and the mechanisms underlying its role in cellular signal transduction have not yet been reported. Herein, we explored the potential roles of WWC3 in lung cancer cells and the corresponding molecular mechanisms. We found low WWC3 expression in both lung cancer cell lines and lung cancer specimens, which was associated with low differentiation, advanced pTNM stage, positive lymph node metastasis, and poor prognosis in patients with lung cancer. Moreover, the overexpression of WWC3 inhibited the proliferation and invasiveness of lung cancer cells. These effects were mediated by the inhibition and stimulation of the Wnt and Hippo pathways, respectively, in vitro and in vivo. Specifically, WWC3 interacts with Dishevelled (Dvl) proteins, prevents casein kinase 1 from phosphorylating Dvls, and inhibits -catenin nuclear translocation to inhibit the Wnt pathway. Deleting the WW and C-terminal PDZ-binding domains of WWC3 abrogated these effects. Moreover, the interaction of WWC3 with Dvls reduced the interaction between WWC3 and large tumour suppressor 1 (LATS1), as well as decreasing LATS1 phosphorylation to increase the nuclear importation of yes-associated protein (YAP) and attenuate the Hippo pathway. Deleting the WW domain of WWC3 abrogated this effect. These findings demonstrate the molecular interplay between WWC3, Dvls, and LATS1, and reveal a link between the Wnt and Hippo pathways, which provides a potential target for clinical intervention in lung cancer.
Introduction
The overstimulation of Wnt signalling can lead to developmental abnormalities and tumour formation [1, 2] . In tumour cells, Wnts, which are proteins secreted by autocrine and paracrine cells, bind to the membrane receptor Frizzled and co-receptor low-density lipoprotein receptor-related protein 5/6 to activate intracellular signalling pathways [3] . The main effector of the Wnt pathway is β-catenin, a transcription factor. When the canonical Wnt pathway is activated, casein kinase 1δ/ε (CK1δ/ε) is activated and phosphorylates Dishevelled (Dvl), which disassembles the destruction complex [4] . Unphosphorylated β-catenin then enters the nucleus, binds to transcription factor Tcf-4, and activates expression of Wnt signalling pathway target genes, such as MYC, CCND1, and MMP7 [5] .
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CTGF, CYR61
, cyclin E, and DIAP [8] , and increases in YAP/TAZ target protein levels increase cell proliferation and decrease apoptosis [9] .
Recent reports have also identified crosstalk between the Wnt and Hippo pathways [10] . Specifically, YAP can interact with cytosolic β-catenin, which hinders β-catenin nuclear import to consequently diminish canonical Wnt signalling [11] . Moreover, nuclear β-catenin can increase YAP transcription and translation to promote colorectal cancer progression [12] . Furthermore, mutations in APC undermine the LATS-SAV1 interaction and attenuate Hippo signalling [13] . Varelas et al reported that cytosolic TAZ (a YAP homologue) can bind to Dvls and block the casein kinase 1ε (CK1ε)-mediated phosphorylation of Dvls, thereby inhibiting the Wnt pathway [14] . However, YAP has not yet been reported to have similar effects.
WWC3 is a member of the WWC protein family (KIBRA/WWC1, WWC2, and WWC3). By interacting with LATS, WWCs act as upstream activators of the Hippo pathway [15] , but few studies, which have primarily focused on WWC1, have reported the roles of WWCs in human tumours, and the relationship between WWC2, WWC3 and human tumours has not yet been reported. Encoded by genes located on different chromosomes, WWCs have a highly conserved molecular structure. Specifically, they contain two WW domains in the N-terminal region that can interact with binding partners harbouring PPxY motif(s) and activate the Hippo pathway. The central part of WWCs consists of a C2 lipid-binding domain and protein kinase C (PKC)-binding sites (regulating cell polarity), whereas the C-terminus contains a PDZ-binding motif (−ADDV) [16, 17] .
Therefore, we examined the WW and ADDV domains in WWCs. We speculate that the WW domain and the C-terminal ADDV domain may, respectively, interact with the PY motif and PDZ domain in Dvls, which are important molecules of the Wnt pathway that primarily act through its PDZ domain. Accordingly, we hypothesize that WWCs can regulate the Wnt pathway by binding to Dvls via ADDV domains to regulate the Hippo pathway via the PPxY motif and regulate the crosstalk between the Wnt and Hippo signalling pathways. In this study, we first examined the expression level of WWC3 in resected lung cancer specimens and lung cancer cells. We also investigated the effects of WWC3 on the proliferation and invasiveness of lung cancer cells. At the molecular level, we demonstrated that WWC3 directly bound Dvls, and elucidated the role of this complex in the crosstalk between the Hippo and Wnt signalling pathways.
Materials and methods
Cell culture
The HBE cell line was obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The LK2 cell line was a gift from H. Kijima (Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Japan). All other cell lines were obtained from the Shanghai Cell Bank (Shanghai, China), and cultured according to the instructions of the ATCC/CTCC. All cell lines were authenticated by short tandem repeat DNA profiling.
Patients and specimens
We collected 127 tumour specimens, including nonsmall-cell lung cancer (NSCLC) tissues and paired non-tumour tissues (32 patients; >5 cm distal to the primary tumour's edge), from patients (average age: 60 years) who underwent surgery at the First Affiliated Hospital of China Medical University from 2005 to 2014. Written informed consent was obtained from all patients, and all procedures were approved by the Institute Research Ethics Committee (No. 2015 [LS]023, China Medical University). All tumour specimens were obtained during surgical resection, and all patients were chemotherapy-naive and radiotherapy-naive prior to resection. According to the 2015 classification criteria of the World Health Organization for lung cancer [18] , 73 and 54 patients presented with adenocarcinoma and squamous cell carcinoma, respectively. According to the 2010 International Union of cancer TNM staging standards [19] , 99 tumours were classified as phase I and II, and 28 tumours were classified as phase III. Of the 127 patients examined, complete follow-up data were available for 93.
Immunohistochemistry (IHC)
Assays were performed as described previously [9] . Briefly, tissue sections were incubated with WWC3 rabbit polyclonal antibody (#HPA039814, 1:200; Sigma, St. Louis, MO, USA). The intensity of WWC3 staining was scored as follows: 0 (no staining), 1 (weak), 2 (moderate), or 3 (high). Percentage scores were assigned as follows: 1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). The scores of each tumour sample were multiplied to give a final score of 0-12, and tumour samples with scores of ≥4 were considered to have positive WWC3 expression, those with scores between 1 and 4 were considered to have weak expression, and those with scores of 0 were considered to have negative expression. Phosphate-buffered saline (PBS) and goat serum were used as negative controls.
Immunoblotting analysis and immunoprecipitation
Assays were performed as described previously [11] . IC261 (sc-3561) was purchased from Santa Cruz Biotechnology, Inc. CA, USA. Expression was quantified by the use of densitometry and ImageJ software. Information on primary antibodies is provided in supplementary material, Supplementary materials and methods.
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Plasmid construction and transfection
Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) transfection reagent was used for plasmid transfection. G418 (#A1720; Sigma) was used to screen stably transfected cells. Information on plasmids is provided in in supplementary material, Supplementary materials and methods.
Dual-luciferase assay
Assays were performed as described previously [11] . Briefly, recombinant human Wnt3a (#5036-WN; R&D Systems, Minneapolis, MN, USA) was reconstituted in PBS containing 0.1% bovine serum albumin to a concentration of 10 μg/ml, and used in experiments at a final concentration of 50 ng/ml. Luciferase reporter plasmids are described in detail in in supplementary material, Supplementary materials and methods.
RNA extraction and reverse transcription quantitative polymerase chain reaction (RT-qPCR) Assays were performed as described previously [11] . The relative transcript levels of genes were normalized to β-actin (ACTB) mRNA levels, and the primer sequences are shown in supplementary material, Supplementary materials and methods.
Colony formation, Matrigel invasion, and MTT assays
Cells were seeded in three 6-cm cell culture dishes (1000 per dish) and incubated for 12 days. The plates were then washed with PBS and stained with Giemsa before counting of the number of colonies consisting of >50 cells.
Matrigel invasion and MTT assays were used in this study. The detailed protocol is provided in in supplementary material, Supplementary materials and methods. All experiments were performed in triplicate.
Immunofluorescence staining
Cells were fixed, permeabilized and incubated with primary antibodies and fluorescein isothiocyanateconjugated or tetramethylrhodamine isothiocyanateconjugated secondary antibodies. Nuclei were stained with 4 ′ ,6-diamidino-2-phenylindole (DAPI), and cells were observed under a confocal microscope.
Transplantation of tumour cells into nude mice
The nude mice used in this study were treated according to experimental animal ethics guidelines issued by China Medical University. The study was approved by the Institutional Animal Research Committee of China Medical University. Four-week-old female BALB/c nude mice were purchased from Charles River (Beijing, China), and the axilla or tail vein of each mouse was subcutaneously or intravenously inoculated with 5 × 10 6 or 2 × 10 6 tumour cells, respectively, in 0.2 ml of sterile PBS. Six weeks after inoculation, the mice were killed and autopsied for examination of tumour growth and dissemination. A portion of tissue from the tumour and each organ was fixed in 4% formaldehyde (Sigma) and embedded in paraffin. Serial 4-μm-thick sections were cut and stained with haematoxylin and eosin, and examined under a microscope. The proliferation rate was evaluated by counting Ki67-positive nuclei in >30 high-power fields per group.
Statistical analysis
The statistical software SPSS 22.0 (SPSS, Chicago, IL, USA) was used for all analyses. The chi-squared test was used to assess correlations between WWC3 expression and clinicopathological factors. The Cox regression model was used to test the prognostic value. All clinicopathological parameters were included in Cox regression model, and tested by univariate analysis with the enter method and by multivariate analysis with the forward stepwise logistic regression method. Differences between the groups were tested with Student's t-test. A P value of <0.05 was considered to be significant.
Results
Low WWC3 expression in NSCLC correlates with poor prognosis WWC3 expression was assessed by IHC in 127 NSCLC samples and 32 paired non-cancerous samples. WWC3 was strongly expressed in the cytoplasm of cells of the bronchial epithelium and submucosal glands. Specifically, WWC3 expression was detected in 87.5% (28/32) of adjacent normal lung tissues, whereas 56.7% of lung cancer samples (72/127) were negative for WWC3 expression ( Figure 1A ; supplementary material, Figure S1 ). Additionally, RT-qPCR indicated that WWC3 mRNA expression was lower in lung cancer than in matched surrounding tissues (20/22; Figure 1B ), and this difference was recapitulated at the protein level as shown by immunoblotting (P = 0.0107; supplementary material, Figure S2A , B). In a panel of human lung cancer cell lines (n = 6), WWC3 expression was lower than in the normal bronchial epithelial cell line HBE ( Figure 1C) , and a statistical analysis indicated that low WWC3 expression in NSCLC positively correlated with poor differentiation, advanced pTNM stage, and positive lymph node metastasis (P = 0.009, P = 0.006, and P = 0.020, respectively; Table 1 ), but was not related to age, gender, and histological type (P > 0.05; Table 1 ). A Kaplan-Meier survival analysis showed that survival was significantly shorter for patients with low WWC3 expression (34.1 ± 3.1 months) than for patients expressing higher levels of WWC3 (52.2 ± 2.1 months) (P = 0.010; Figure 1D ). Cox univariate and multivariate analyses revealed that a high TNM stage and negative WWC3 expression (P = 0.014 and P = 0.045, respectively; Table 2 ) were independent prognostic factors in NSCLC.
WWC3 inhibits the proliferation and invasion of NSCLC cells in vivo and in vitro
To verify the biological function of WWC3 in NSCLC, we transfected H1299 and LK2 cells (which show low WWC3 expression) with the WWC3 plasmid. As compared with the control group, WWC3 overexpression inhibited the colony formation, proliferation (MTT assay) and invasiveness of H1299 and LK2 cells (Figure 2Aa To assess the effect of WWC3 on proliferation and invasion in vivo, H1299/LK2 and A549/SPC cell lines stably expressing WWC3 or in which WWC3 WWC3 inhibits invasion and metastasis 439 was knocked down (selected by G418) were subcutaneously injected or intravenously injected via the tail vein into nude mice. Although the tumour formation rate was similar (5/5, 100%), the volume and weight of subcutaneously injected tumours were reduced in the WWC3 group as compared with the control group (H1299: WWC3 versus control volume, 0.52 ± 0.08 cm 3 versus 1.18 ± 0.18 cm 3 , P < 0.05; weight, 0.51 ± 0.07 g versus 1.07 ± 0.15 g, P < 0.01) (Figure 2Ba-c; supplementary material, Figure  S3Ba -c). WWC3 knockdown had the opposite effect (A549: short hairpin RNA (shRNA)-WWC3 versus control volume, 1.22 ± 0.11 cm 3 versus 0.53 ± 0.10 cm 3 , P < 0.01; weight, 1.02 ± 0.14 g versus 0.51 ± 0.13 g, P < 0.05) ( Figure 2 Bd-f; supplementary material, Figure S3Bd -f). After intravenous injection, as compared with the control group, WWC3 overexpression reduced the lung weight (H1299: WWC3 versus control, 0.452 ± 0.028 g versus 0.854 ± 0.036 g, P < 0.001) and intrapulmonary metastasis formation (H1299: WWC3 versus control, 1/4 versus 3/4), whereas WWC3 knockdown had the opposite effect (A549: shWWC3 versus control lung weight, 0.781 ± 0.040 g versus 0.470 ± 0.029 g, P < 0.01; lung metastasis rate, 4/4 versus 2/4) ( Figure 2C ; supplementary material, Figure  S3C ). Consistently, positive Ki67 staining indicated a lower proliferation rate in lung tumours overexpressing WWC3 (WWC3 versus control, 26 ± 3 versus 63 ± 5, P < 0.01), whereas the opposite was observed in WWC3 knockdown tumours (shWWC3 versus control, 52 ± 5 versus 21 ± 2; P < 0.01; supplementary material, Figure  S4A , B). Taken together, these data suggested that WWC3 may function as a negative regulator of lung tumour progression both in vitro and in vivo.
WWC3 inhibits the Wnt pathway and activates the Hippo pathway
To gain insights into the mechanism underlying the inhibition of lung cancer cell proliferation and invasion by WWC3 and its possible effects on the Wnt and Hippo pathways, we selected A549/SPC and H1299/LK2 cells showing relatively high and low WWC3 expression, respectively. We assessed the effect of WWC3 on the activities of the Wnt and Hippo pathways in these cell lines by using luciferase reporter assays. To readily observe differences, we prestimulated the Wnt signalling pathway with Wnt-3A [20] . In H1299 and LK2 cells, WWC3 overexpression significantly reduced the TOPflash activity of Wnt signalling induced by Wnt3A, whereas WWC3 silencing in A549 and SPC cells had the opposite effect (Figure 3A , B; supplementary material, Figure 5A, B) . Similarly, we examined the effect of WWC3 on the activity of Hippo signalling. WWC3 overexpression significantly reduced TEAD transcriptional activity in H1299 and LK2 cells, which indicated Hippo pathway activation. In A549 and SPC cells, WWC3 knockdown had the opposite effect (Figure 3C , D; supplementary material, Figure S5C, D) . In the H292 cell line, we both overexpressed and silenced WWC3 expression. Luciferase reporter assays indicated the same phenomena (supplementary material, Figure442 
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To further confirm these results, we detected changes in the expression of key factors in the Wnt and Hippo signalling pathways and their target genes after overexpression or knockdown of WWC3 expression. WWC3 overexpression significantly downregulated non-phosphorylated β-catenin, cyclin D1, matrix metalloproteinase-7 (MMP7) and c-myc at both the protein and mRNA levels, and these changes consequently resulted in downregulation of CTGF and cyclinE, which are Hippo-related genes, at the protein and mRNA levels (Figure 3E, F; and supplementary material, Figure S5I, J) . Conversely, WWC3 knockdown in A549 cells upregulated the expression of Wnt-related and Hippo-related genes (Figure 3E , G; supplementary material, Figure S5I , K). Furthermore, confocal microscopy indicated that WWC3 silencing promoted β-catenin nuclear import ( Figure 3H ). These results indicate that WWC3 negatively regulates Wnt signalling and is a positive regulator of Hippo signalling.
The WW and ADDV domains of WWC3 interact with the PY motif and PDZ domain of Dvl2, respectively
To verify that WWC3 can interact with Dvls, coimmunoprecipitation was performed to detect the interaction between endogenous WWC3 and three Dvl isoforms (1, 2, and 3) in A549 cells ( Figure 4A ; supplementary material, Figure S6B, C) . Because the expression of Dvl2 was higher than that of other Dvls, we selected Dvl2 to represent all Dvls in subsequent experiments. This interaction was also demonstrable after cotransfection with FLAG-tagged Dvl2 and green fluorescent protein (GFP)-tagged WWC3 plasmids (supplementary material, Figure S6A) . A glutathione-S-transferase (GST) pulldown assay indicated that WWC3 could interact with Dvl2 directly ( Figure 4B ). Also, confocal microscopy indicated that WWC3 and Dvl2 were colocalized ( Figure 4C ). To localize the binding sites involved in the interaction between WWC3 and Dvl2, we constructed a series of WWC3 and Dvl2 mutant plasmids ( Figure 4D, E) . Coimmunoprecipitation results showed that the WW and ADDV domains both contributed to the association of WWC3 with Dvl2, whereas this interaction was abrogated upon the deletion of both the WW and ADDV domains ( Figure 4F) . Conversely, an analysis of the binding of several Dvl2 mutants to WWC3 demonstrated that the PDZ domain and PY motif located at amino acids 564-568 both contributed to the interaction with WWC3, whereas this interaction was abrogated upon the deletion of both the PDZ domain and PY motif ( Figure 4G ). After cotransfection with WWC3-ΔADDV and Dvl2-ΔPDZ mutant plasmids, the WW domain of WWC3 and the PY motif of Dvl2 were able to interact ( Figure 4H) . Similarly, when retained, the ADDV domain of WWC3 and the PDZ domain of Dvl2 were able to interact ( Figure 4I ). These results show that the WWC3 WW and ADDV domains associate with the PY motif and PDZ domain of Dvl2, respectively.
WWC3 and CK1ε competitively interact with Dvl2 and negatively regulate Wnt activity
To explore the specific mechanism underlying the inhibition of Wnt signalling by WWC3, we overexpressed WWC3 in H1299 cells; this showed that Dvl2 phosphorylation was significantly downregulated, whereas WWC3 silencing in A549 cells significantly upregulated Dvl2 phosphorylation ( Figure 5A ). Varelas et al reported that increased cytosolic TAZ due to Hippo pathway activation decreased Dvl2 phosphorylation [14] , and we also demonstrated that WWC3 activated the Hippo pathway. Therefore, the WWC plasmid and small interfering RNA (siRNA)-TAZ were cotransfected into H1299 cells; this showed that WWC3 overexpression decreased Dvl2 phosphorylation independently of TAZ (supplementary material, Figure S7 ). Moreover, luciferase reporter assays indicated that CK1δ/ε knockdown in A549 cells reversed the increase in TOPflash signals caused by WWC3 silencing ( Figure 5B ), and immunoblotting showed that the CK1δ/ε inhibitor IC261 [21] or siRNA-CK1δ/ε transfection in A549 cells attenuated the increases in Dvl2 phosphorylation induced by WWC3 knockdown (Figure 5C, D) . Furthermore, WWC3 plasmids were transfected into H1299 cells, and coimmunoprecipitation showed that the interaction between CK1ε and Dvl2 inversely correlated with WWC3 expression. H1299 cells were also transfected with the CK1ε plasmid, which demonstrated that the interaction between WWC3 and Dvl2 was inversely correlated with CK1ε expression ( Figure 5E ). These results show that WWC3 and CK1ε competitively interact with Dvl2.
We also transfected wild-type and mutant WWC3 plasmids into H1299 cells, and conducted luciferase reporter assays. Wild-type WWC3 attenuated Wnt signalling induced by Wnt3A, but WWC3-ΔWW&ADDV, which cannot interact with Dvl2, abrogated this effect ( Figure 5F ). Immunoblotting showed that transfection with wild-type WWC3 plasmids reduced the levels of non-phosphorylated β-catenin and phosphorylated Dvl2, as well as downregulating target genes of the Wnt pathway. The deletion of both the WW and ADDV domains of WWC3 abrogated this effect, whereas the single mutants WWC3-ΔWW (Mutant1) and WWC3-ΔADDV (Mutant2) slightly downregulated β-catenin, phosphorylated Dvl2, and target gene expression ( Figure 5G ). Taken together, these results suggest that the interaction between WWC3 and Dvl2 blocked CK1ε-mediated Dvl2 phosphorylation to negatively regulate Wnt signalling.
Dvl2 and LATS1 competitively bind to WWC3 to regulate Hippo signalling Figure S8A , B), which signifies Hippo signalling inhibition.
We then transfected wild-type and three mutant WWC3 constructs into H1299 cells, and performed luciferase reporter assays. The deletion of the
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This indicated that the WW domain of WWC3 plays an important role in promoting Hippo signalling. Using immunoprecipitation, we also confirmed that wild-type WWC3 interacts with LATS1, whereas WW domain deletion abrogated this interaction ( Figure 6C ).
Combining our findings with previous results indicating that Dvl2 can associate with the WW domain of WWC3, we hypothesized that Dvl2 can compete with LATS1 for binding to WWC3 to affect Hippo signalling. To verify this hypothesis, we overexpressed or silenced Dvl2 in H1299 cells. Immunoprecipitation indicated that Dvl2 overexpression decreased the interaction between WWC3 and LATS1 ( Figure 6D ), whereas Dvl2 silencing increased this interaction ( Figure 6E ). Moreover, LATS1 overexpression in H1299 cells decreased the interaction between WWC3 and Dvl2 ( Figure 6F ), whereas LATS1 silencing increased the interaction between WWC3 and Dvl2 ( Figure 6G ). These results proved that LATS1 and Dvl2 bind competitively to WWC3. Immunoblotting showed that Dvl2 overexpression reversed the increases in p-LATS1 and p-YAP levels induced by WWC3 overexpression ( Figure 6H ). Cotransfection with WWC3 and siRNA-Dvl2 further upregulated p-YAP and p-LATS1 ( Figure 6I ). Finally, we cotransfected WWC3 with Dvl2 or Dvl2 mutants into H1299 cells, and this showed that wild-type Dvl2 reverses the increases in p-LATS1 and p-YAP levels induced by WWC3 by interacting with WWC3, whereas Dvl2 Mutant3 (in which both the PDZ domain and PY motif were deleted), which cannot bind to WWC3, had no such effect ( Figure 6J) . Thus, the WWC3-Dvl2 interaction inhibits the formation of the WWC3-LATS1 complex to inhibit Hippo signalling.
Discussion
Several pathways contribute to the regulation of tissue growth and tumourigenesis, especially Hippo and Wnt signalling. Specifically, both Hippo pathway inhibition and Wnt pathway stimulation pave the way for tumourigenesis, but the crosstalk between Hippo and Wnt signalling to coordinate these processes remains unclear. Herein, we have shown that the scaffolding protein WWC3, an upstream activator of the Hippo pathway, can inhibit Wnt-β-catenin signalling and the proliferation and invasion of lung cancer cells.
WWC3, a homologue of KIBRA/WWC1, is a member of the WWC protein family. KIBRA/WWC1 has been implicated in some cancers [22] , such as osteosarcoma, in which decreased WWC1 expression has been shown to maintain osteosarcoma cell stemness [23] . WWC1 can inhibit the epithelial-mesenchymal transition of breast cancer cells [24] , and WWC1 methylation status is a prognostic factor in chronic lymphocytic leukaemia [25] . WWC1 is therefore considered to be a tumour suppressor. However, in gastric cancer, high WWC1 expression and low atypical PKC (aPKC) expression correlated with poor prognosis and lymph node metastasis [26] , and WWC1 promotes prostate cancer cell proliferation and migration [27] . These data suggest that the roles of WWCs in human tumours are complex, and that many mechanisms underlying these roles remain to be revealed.
Here, we found that WWC3 expression is downregulated in NSCLC and in lung cancer cell lines, and that this downregulation is positively correlated with poor differentiation, advanced pTNM stage, positive lymph node metastasis, and the poor prognosis of patients with NSCLC. In vitro and in vivo experiments demonstrated that WWC3 can inhibit lung cancer cell proliferation, migration, and invasiveness. Therefore, WWC3 acts as a tumour suppressor in lung cancer, but the cause of its reduced expression, e.g. methylation, gene mutation, or tissue specificity, requires further study. Additionally, most annotated WWC3 sequences lack WW domains; the molecular mass of the full-length WWC3 open reading frame is predicted to be 136 kDa (GenBank Accession No. KC987947). However, owing to multiple post-translational phosphorylation and/or glycosylation modifications, we occasionally detect endogenous WWC3 in cell lysates as a band at 160-170 kDa.
Cell and biological behaviours are modulated by sophisticated and dynamic protein-protein networks, and scaffolding proteins are crucial for these processes. We confirmed that WWC3 interacts with the PY motif and PDZ domain of Dvl2 via its WW domain and ADDV domain, respectively. This interaction blocks CK1ε-induced Dvl2 phosphorylation, reduces β-catenin nuclear import, and inhibits Wnt signalling. Furthermore, LATS1 can compete with Dvl2 for binding to the WW domain of WWC3, and the WWC3-LATS1 interaction increases LATS1 phosphorylation independently of MST phosphorylation, which consequently stimulates Hippo signalling. Thus, the role of WWC3 as a tumour suppressor probably depends on the competitive interaction between DVLs and LATS1 (supplementary material, Figure S9 ). WWC3 thus constitutes an upstream link between the Wnt and Hippo pathways that may be a useful target for drug development in lung cancer. Figure S1 . The expression of WWC3 in normal bronchial epithelial cells 
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